Welcome to LookChem.com Sign In|Join Free
  • or
Methyl 5-nitro-1H-pyrrolo[2,3-b]pyridine-2-carboxylate is an organic compound that belongs to the class of azaindole derivatives. It is characterized by the presence of a nitro group at the 5-position and a carboxylate group at the 2-position, which are attached to a pyrrolo[2,3-b]pyridine ring. methyl 5-nitro-1H-pyrrolo[2,3-b]pyridine-2-carboxylate has potential applications in the pharmaceutical industry due to its unique chemical structure and properties.

952182-17-1

Post Buying Request

952182-17-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

952182-17-1 Usage

Uses

Used in Pharmaceutical Industry:
Methyl 5-nitro-1H-pyrrolo[2,3-b]pyridine-2-carboxylate is used as a key intermediate in the synthesis of inhibitors targeting Abl and Src protein kinases. These protein kinases are involved in various cellular processes, including cell growth, differentiation, and apoptosis. Inhibition of these kinases can lead to the regulation of abnormal cell signaling and has potential therapeutic benefits in the treatment of various diseases, such as cancer and inflammatory disorders.
In the preparation of Abl kinase inhibitors:
Methyl 5-nitro-1H-pyrrolo[2,3-b]pyridine-2-carboxylate serves as a crucial building block in the development of Abl kinase inhibitors. Abl kinases, including Abl1 and Abl2, are non-receptor tyrosine kinases that play a significant role in cell signaling pathways. Dysregulation of Abl kinases has been implicated in various diseases, such as chronic myeloid leukemia (CML) and other malignancies. By inhibiting Abl kinases, these inhibitors can help control the progression of these diseases and improve patient outcomes.
In the preparation of Src kinase inhibitors:
Methyl 5-nitro-1H-pyrrolo[2,3-b]pyridine-2-carboxylate is also utilized in the synthesis of Src kinase inhibitors. Src kinases are a family of non-receptor tyrosine kinases that are involved in various cellular processes, including cell adhesion, migration, and proliferation. Abnormal activation of Src kinases has been associated with several diseases, such as rheumatoid arthritis, osteoporosis, and cancer. Inhibiting Src kinases can help modulate these pathological processes and provide therapeutic benefits in the treatment of these conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 952182-17-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,2,1,8 and 2 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 952182-17:
(8*9)+(7*5)+(6*2)+(5*1)+(4*8)+(3*2)+(2*1)+(1*7)=171
171 % 10 = 1
So 952182-17-1 is a valid CAS Registry Number.
InChI:InChI=1/C9H7N3O4/c1-16-9(13)7-3-5-2-6(12(14)15)4-10-8(5)11-7/h2-4H,1H3,(H,10,11)

952182-17-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl 5-nitro-1H-pyrrolo[2,3-b]pyridine-2-carboxylate

1.2 Other means of identification

Product number -
Other names 5-nitro-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid methyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:952182-17-1 SDS

952182-17-1Relevant academic research and scientific papers

NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES

-

Page/Page column 148, (2010/06/17)

This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 952182-17-1